Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review
Annals of Pharmacotherapy · 2024-07 · 58 (7) · 742-755
DOI: 10.1177/10600280231204969 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 26.10.2023. Verfasst von Michael Cristian Garcia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Toxicology Research Group, St. Joseph's Healthcare, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Chloroquine, Hydroxychloroquine, Long QT Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
We aimed to evaluate the high-quality literature on the frequency and nature of major adverse cardiac events (MACE) associated with either hydroxychloroquine (HCQ) or chloroquine (CQ). Data sources: We searched Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Central from 1996 onward using search strategies created in collaboration with medical science librarians. Study selection and data extraction: Randomized controlled trials (RCTs) published in English language from January 1996 to September 2022, involving adult patients at least 18 years of age, were selected. Outcomes of interest were death, arrhythmias, syncope, and seizures. Random-effects meta-analyses were performed with a Treatment Arm Continuity Correction for single and double zero event studies. Data synthesis: By study drug, there were 31 HCQ RCTs (n = 6677), 9 CQ RCTs (n = 622), and 1 combined HCQ-CQ trial (n = 105). Mortality was the most commonly reported MACE at 220 of 255 events (86.3%), with no reports of torsades de pointes or sudden cardiac death. There was no increased risk of MACE with exposure to HCQ-CQ compared with control (risk ratio [RR] = 0.90, 95% CI = 0.69-1.17, I 2 = 0%). Relevance to patient care and clinical practice: These findings have important implications with respect to patient reassurance and updated guidance for prescribing practices of these medications.
Conclusions
Despite listing as QT-prolonging meds, HCQ-CQ did not increase the risk of MACE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology & Toxicology Research Group, St. Joseph's Healthcare, Hamilton, ON, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
- Biostatistics Unit, Father Sean O'Sullivan Research Centre, St. Joseph's Healthcare, Hamilton, ON, Canada.
- Division of Clinical Pharmacology & Toxicology, Department of Medicine, St. Joseph's Healthcare, Hamilton, ON, Canada.
ORCID-Profile: Michael Cristian Garcia, Jessyca Matos Silva, Anne Holbrook
Zitieren
APA
Garcia, M. C., Tsang, K., Lohit, S., Deng, J., Schneider, T., Matos Silva, J., Mbuagbaw, L., & Holbrook, A. (2024). Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review. Annals of Pharmacotherapy, 58(7), 742-755. https://doi.org/10.1177/10600280231204969
Vancouver
Garcia MC, Tsang K, Lohit S, Deng J, Schneider T, Matos Silva J, et al. Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review. Annals of Pharmacotherapy. 2024;58(7):742-755. doi:10.1177/10600280231204969
BibTeX
@article{Garcia2024,
author = {Garcia, Michael Cristian and Tsang, Kai La and Lohit, Simran and Deng, Jiawen and Schneider, Tyler and Matos Silva, Jessyca and Mbuagbaw, Lawrence and Holbrook, Anne},
title = {Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review},
journal = {Annals of Pharmacotherapy},
year = {2024},
volume = {58},
number = {7},
pages = {742--755},
doi = {10.1177/10600280231204969}
}
EUVIMED